Answers are grounded in this paper and cite their sources.
The neonate is a relatively immunocompromised host. Deficiencies in both the neutrophilmacrophage phagocytic system and antibodymediated immunity contribute to the risk for bacterial sepsis, a life-threatening condition with a 20% to 75% mortality rate. 1-3 Previous studies have suggested the benefit of granulocyte transfusions and intravenous gamma globulin in the treatment of neonatal sepsis. 4,5 Recently, success using recombinant human granulocyte colony-stimulating factor (rhG-CSF) for chemotherapy-induced and congenital neutropenia 6 has led to investigations using this hematopoietic cytokine during neonatal sepsis. Data from neonatal rat models demonstrate the effectiveness of rhG-CSF therapy during experimental sepsis. 7-9 Results of preliminary biological studies of the efficacy and toxicity of rhG-CSF in human neonatal sepsis also appear favorable. 10 We describe a premature neonate with Escherichia coli sepsis and neutropenia who was given rhG-CSF and responded with an increased neutrophil count and rapid resolution of sepsis. Patient Report. A 1580-g male infant was
No takes yet. Share an insight, caveat, or question.
Jeffrey C. Murray (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: